博雅生物(300294) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥684,026,058.95, a decrease of 4.55% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥139,440,739.05, an increase of 10.89% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥108,414,674.24, down 12.90% from the previous year[5]. - The basic earnings per share for the quarter was ¥0.2800, a decrease of 6.67% compared to the same period last year[5]. - The total profit amounted to CNY 504,028,174.17, compared to CNY 394,684,389.63 in the previous period, reflecting an increase of about 27.7%[36]. - The operating profit reached CNY 505,255,213.36, up from CNY 392,621,590.85, indicating a growth of approximately 28.7%[36]. - The net profit attributable to shareholders of the parent company was CNY 418,279,088.07, an increase from CNY 323,458,914.31 in the previous period, representing a growth of approximately 29.3%[37]. - The total comprehensive income amounted to CNY 428,899,020.70, compared to CNY 349,903,789.47 in the previous period, reflecting an increase of approximately 22.5%[37]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,979,553,465.16, reflecting a 4.69% increase from the end of the previous year[5]. - The equity attributable to shareholders increased to ¥7,171,716,020.94, up 5.02% from the previous year[5]. - The company's total liabilities as of September 30, 2022, were CNY 711,315,701.71, compared to CNY 701,299,849.03 at the beginning of the year[30]. - The company's total current assets reached CNY 5,991,275,687.02, up from CNY 5,645,912,964.89 at the beginning of the year[25]. Cash Flow - The cash flow from operating activities showed a significant decline of 67.87% year-on-year, totaling ¥377,007,297.33[5]. - The cash flow from operating activities was CNY 377,007,297.33, down from CNY 1,173,508,351.28 in the previous period, showing a decline of approximately 67.9%[42]. - Cash inflow from investment activities totaled CNY 3,448,467,134.16, significantly higher than CNY 578,069,667.36 in the previous period, marking an increase of about 497.5%[42]. - The net cash flow from investment activities was negative at CNY -778,543,985.54, slightly improved from CNY -788,695,949.14 in the previous period[45]. Investments and Expenses - The company's cash and cash equivalents decreased by 30.60% to ¥1,099,155,602.26 due to investments in financial products[10]. - The company's intangible assets increased by 57.35% to ¥266,665,134.59, primarily due to the transfer of R&D projects[10]. - R&D expenses decreased by 31.85% to ¥35,626,723.74, primarily due to the capitalization of certain projects[13]. - Investment income increased by 587.91% to ¥48,175,581.16, mainly driven by higher returns from financial products[13]. - Cash paid for investments surged by 216.32% to ¥4,150,000,000.00, primarily due to increased purchases of financial products[13]. - The company reported a significant increase in financial expenses by 606.60% to -¥18,322,375.98, due to increased interest income from bank deposits[13]. Strategic Developments - The company established a new subsidiary, Yangcheng Plasma Station, holding an 80% stake, to enhance strategic cooperation in the blood products sector[19]. - The company obtained the drug registration certificate for human coagulation factor VIII in August 2022, enhancing its product line and increasing the value of plasma utilization per ton[20]. - The company's subsidiary, Tianan Pharmaceutical, received the drug registration certificate for acarbose tablets in September 2022, which will strengthen its diabetes medication product line and market competitiveness[21]. - The company is focused on expanding its product offerings and enhancing its market position through strategic product registrations and certifications[20][21]. Other Information - Deferred tax assets rose by 37.23% to ¥37,655,335.12, mainly due to changes in the fair value of financial products[13]. - Long-term borrowings decreased by 100% as they were reclassified to current liabilities[13]. - Other non-current assets increased by 41.14% to ¥52,503,771.62, primarily due to land deposit payments[13]. - Contract liabilities increased by 39.25% to ¥18,067,719.38, reflecting an increase in advance payments received[13]. - The third quarter report has not been audited[46]. - The board of directors of China Resources BoYa Bio-Pharmaceutical Group Co., Ltd. held a meeting on October 24, 2022[47].